Abstract B015: 3D Organoid-Based Therapeutics with Translational Potential in Cancer Immunity and Autoimmune Risk Prediction

Organoids represent a transformative advancement in cancer research: 3D models that mimic in vivo tumor behavior. In this study, we present a nano-sized in vitro-vivo organoid system designed to improve therapeutic monitoring and predictive accuracy in cancer treatment. We observed significant increases in organoid survival in treated groups (p < 0.01). Organoids' true potential lies in expansion by integrating immune components such as CD8+ T cells or checkpoint blockade agents; this system could model immune surveillance, cytotoxicity, and even autoimmune toxicity associated with immunotherapies. As personalized medicine advances, anticipate immune-related adverse events and study tumor-immune escape mechanisms in a controlled, patient-specific environment. This study provides the foundation for a next-generation organoid platform that bridges the gap between preclinical drug screening and mechanistic studies in cancer immunity and autoimmunity, paving the way for safer, more effective immunotherapeutic strategies. Citation Format: Md Noushad Javed, SDanish Kadir. 3D Organoid-Based Therapeutics with Translational Potential in Cancer Immunity and Autoimmune Risk Prediction [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B015.